A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding of Mtb biology. We attempt to bridge this gap by carrying out extensive re-annotation and constructing a systems level protein interaction map of Mtb with an objective of finding novel drug target candidates. Towards this, we synergized crowd sourcing and social networking methods through an initiative ‘Connect to Decode’ (C2D) to generate the first and largest manually curated interactome of Mtb termed ‘interactome pathway’ (IPW), encompassing a total of 1434 proteins connected through 2575 functional relationships. Interactions leading to gene regulation, signal transduction, metabolism, structural complex formation have been catalogued. In the process, we have functionally annotated 87% of the Mtb genome in context of gene products. We further combine IPW with STRING based network to report central proteins, which may be assessed as potential drug targets for development of drugs with least possible side effects. The fact that five of the 17 predicted drug targets are already experimentally validated either genetically or biochemically lends credence to our unique approach.
We report Metagenome from the saline desert soil sample of Little Rann of Kutch, Gujarat State, India. Metagenome consisted of 633,760 sequences with size 141,307,202 bp and 56% G + C content. Metagenome sequence data are available at EBI under EBI Metagenomics database with accession no. ERP005612. Community metagenomics revealed total 1802 species belonged to 43 different phyla with dominating Marinobacter (48.7%) and Halobacterium (4.6%) genus in bacterial and archaeal domain respectively. Remarkably, 18.2% sequences in a poorly characterized group and 4% gene for various stress responses along with versatile presence of commercial enzyme were evident in a functional metagenome analysis.
<p>Pneumonia of unknown
cause detected in Wuhan, China was first reported to the WHO Country Office in
China on 31 December 2019. The outbreak was declared a Public Health Emergency
of International Concern on 30 January 2020. Currently, there is no Vaccine
against COVID-19 pandemic and infection is spreading worldwide vary rapidly
there is an exigent requirement of practicable drug treatment. Drug repurposing
is one of the most promising approaches for that. Many reports are available
with <i>in silico</i> drug repurposing but the majority of them engrossed on a
single target. The present study aimed at screening the approved against
Covid19 protein and extract the combination of operational comprehensively. A total
of 1735 drug molecules against all COVID19 protein structures and sequential
screening recognize the better potential of anti-HCV drugs over anti-HIV drugs.
The study designated Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir,
Antrafenine Ergotamin as promising drug candidates for covid19 treatment. The
computational analysis also reveled the better potential of proposed drugs over
the currently used drug combination for COVID19 drugs. </p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.